Treatment of metastatic melanoma targeting genetically activated oncogene pathways (BRAF/NRAS/KIT pathways) and so-called immune-checkpoints have significantly improved overall survival rates of metastatic melanoma patients in recent years [1,2]. The gene discussed is KIT; the disease is metastatic melanoma.